EOLSHIGH SIGNALFINANCIAL10-K

EOLS experienced a dramatic financial deterioration with stockholders' equity collapsing from $5.5M to -$23.1M, creating a negative equity position while operating cash flow losses more than doubled.

The company has moved into negative stockholders' equity territory, indicating liabilities now exceed assets and signaling severe financial distress. Combined with dramatically worsening operating cash flows and declining cash reserves, this suggests potential liquidity concerns and possible going concern issues that investors should monitor closely.

Comparing 2026-03-03 vs 2025-03-04View on EDGAR →
FINANCIAL ANALYSIS

EOLS shows clear signs of financial deterioration across multiple metrics, with stockholders' equity plunging 518% into negative territory while operating cash flow losses more than doubled to -$42.3M. The company burned through $33.2M in cash reserves while simultaneously increasing debt by $24.6M and doubling inventory levels to $27.0M, suggesting potential demand challenges. Interest expenses surged 52% reflecting the higher debt burden, while increased capex and R&D spending indicate continued investment despite the cash burn, creating a concerning mismatch between financial resources and spending trajectory.

FINANCIAL STATEMENT CHANGES
Stockholders Equity
Balance Sheet
-518.4%
$5.5M→-$23.1M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Operating Cash Flow
Cash Flow
-134.8%
-$18.0M→-$42.3M

Operating cash flow fell 134.8% — earnings quality concerns; investigate working capital changes and non-cash items.

Capital Expenditure
Cash Flow
+133.8%
$1.5M→$3.4M

Capital expenditure jumped 133.8% — major investment cycle underway; assess returns on deployment.

Inventory
Balance Sheet
+121.8%
$12.2M→$27.0M

Inventory surged 121.8% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Interest Expense
P&L
+52.1%
$9.1M→$13.8M

Interest expense surged 52.1% — significant debt increase or rising rates materially impacting earnings.

Cash & Equivalents
Balance Sheet
-38.1%
$87.0M→$53.8M

Cash declined 38.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Debt
Balance Sheet
+20.2%
$121.5M→$146.1M

Debt rose 20.2% — additional borrowing for investment or operations; monitor coverage ratios.

R&D Expense
P&L
+19.9%
$1.7M→$2.1M

R&D investment increased 19.9% — signals commitment to future product development, though near-term margin impact.

Current Liabilities
Balance Sheet
+19.6%
$63.0M→$75.3M

Current liabilities rose 19.6% — increased short-term obligations, watch current ratio.

Accounts Receivable
Balance Sheet
+14.7%
$47.7M→$54.7M

Receivables grew 14.7% — monitor days sales outstanding for collection efficiency.

LANGUAGE CHANGES
NEW — 2026-03-03
PRIOR — 2025-03-04
ADDED
As of February 27, 2026, 65,059,990 shares of the registrant s sole class of common stock were outstanding.
Securities and Exchange Commission ( SEC ) in the future, including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which may from time to time amend, supplement or supersede the risks and uncertainties we disclose.
Summary of Risk Factors An investment in our securities involves various risks and you are urged to carefully consider the risks discussed under Item 1A Risk Factors, in this Annual Report on Form 10-K prior to making an investment in our securities.
As more fully described in Item 1A Risk Factors, the principal risks and uncertainties that may affect our business, financial condition and results of operations include, but are not limited to, the following: We have incurred significant losses since our inception, and we may continue to incur losses, which could adversely affect the market price of our common stock and our ability to raise additional capital.
Jeuveau , Evolysse Form and Evolysse Smooth face, and any of our future product candidates will face, significant competition and our failure to effectively compete may prevent us from maintaining our market share and expansion.
+7 more — sign up free →
REMOVED
As of February 28, 2025, 63,586,753 shares of the registrant s sole class of common stock were outstanding.
Securities and Exchange Commission, or SEC, in the future, including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which may from time to time amend, supplement or supersede the risks and uncertainties we disclose.
As more fully described in Item 1A Risk Factors , the principal risks and uncertainties that may affect our business, financial condition and results of operations include, but are not limited to, the following: We have incurred significant losses since our inception.
Jeuveau faces, and any of our future product candidates will face, significant competition and our failure to effectively compete may prevent us from maintaining our market share and expansion.
We are dependent on Symatese Aesthetics, S.A.S., or Symatese, to achieve regulatory approval for the Evolysse hyaluronic acid gels product line in the United States and Europe.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →